Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Pfizer and BioNTech entered a co-development and co-commercialization agreement for BioNTech's mRNA COVID-19 vaccine candidates (BNT162 program). Pfizer paid $185M upfront ($72M cash + $113M equity investment) with up to $563M in milestone payments. Development costs were split 50/50, with Pfizer initially funding 100% and BioNTech repaying its share from commercialization. The resulting Comirnaty vaccine generated over $36B in 2021 revenue alone and remains the most commercially successful product of the alliance. Revenue has since normalized sharply from its pandemic peak: Pfizer's FY2025 total revenue was $62.6B (down 2% YoY), with declining COVID-19 product sales the primary driver as US vaccine recommendations narrowed. The franchise also carries a patent-liability overhang: a Dusseldorf court ruled in March 2025 that Pfizer/BioNTech infringed Moderna's mRNA patents and must account for Comirnaty profits and pay compensation (subject to appeal), with parallel US litigation ongoing.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / BioNTech SE (this deal) | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
| Pfizer Inc. / Seagen Inc. | 2023 | $43.0B | 77 |
← Browse all deals · How we score deals
More: 2020 deals · Pfizer Inc. deals · Infectious Disease deals